Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.
OBJECTIVE
The aim of this study was to evaluate the significance of endothelial cell-derived microparticles (EDMP), angiopoietin-2 (Ang-2) and adiponectin in hyperlipidemic patients with and without type 2 diabetes mellitus, and to compare the two for the effects of eicosapentaenoic acid (EPA) on these markers.


METHODS
One hundred and twenty-six hyperlipidemic patients with and without type 2 diabetes mellitus received EPA 1,800 mg daily, and 50 of the patients were non-diabetic.


RESULTS
EDMP and Ang-2 levels prior to treatment were higher in diabetic patients than in non-diabetic patients, whereas adiponectin levels were lower in diabetics. When diabetic patients were classified into two groups on the basis of Ang-2 levels, the levels of all markers remained unchanged in those without a high Ang-2 level after EPA treatment. In contrast, all markers except for adiponectin were decreased significantly in diabetic patients with high Ang-2 levels after 6 months of EPA treatment. These diabetic patients with high Ang-2 levels displayed a more significant increase in adiponectin levels after EPA treatment than those who did not.


CONCLUSIONS
These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels.
Nomura
Shosaku
S
Division of Hematology, Kishiwada City Hospital, Osaka, Japan. shosaku-n@mbp.ocn.ne.jp
Shouzu
Akira
A
Omoto
Seitarou
S
Inami
Norihito
N
Ueba
Tetsuya
T
Urase
Fumiaki
F
Maeda
Yasuhiro
Y
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D042702:Angiopoietin-2 / Q000097:blood*; D055252:Cell-Derived Microparticles / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000494:pharmacology; D042783:Endothelial Cells; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D008297:Male; D008875:Middle Aged; D020011:Protective Agents; D014652:Vascular Diseases / Q000517:prevention & control
D052242:Adiponectin; D042702:Angiopoietin-2; D020011:Protective Agents; D015118:Eicosapentaenoic Acid